Want to join the conversation?
$AMGN Product Update: Today announced the top-line results of a Phase 2 open-label, single-arm, multicenter trial to evaluate the efficacy and safety of BLINCYTO® (blinatumomab) in adults with relapsed or refractory Philadelphia chromosome-positive (Ph ) B-cell precursor acute lymphoblastic leukemia (ALL).
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.